Voyager Therapeutics, Inc. (VYGR) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 34.46M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $34.46M | (m) | (m) |
| 2026-03-31 | (m) | $36.49M | (m) | (m) |
| 2025-12-31 | (m) | $40.37M | (m) | (m) |
| 2025-09-30 | (m) | $31.32M | (m) | (m) |
| 2025-06-30 | (m) | $42.58M | (m) | (m) |
| 2025-03-31 | (m) | $66.96M | (m) | (m) |
| 2024-12-31 | (m) | $80.00M | (m) | (m) |
| 2024-09-30 | (m) | $64.28M | (m) | (m) |
| 2024-06-30 | (m) | $44.26M | (m) | (m) |
| 2024-03-31 | (m) | $19.54M | (m) | (m) |
| 2023-12-31 | (m) | $250.01M | (m) | (m) |
| 2023-09-30 | (m) | $158.40M | (m) | (m) |
| 2023-06-30 | (m) | $194.87M | (m) | (m) |
| 2023-03-31 | (m) | $190.73M | (m) | (m) |
| 2022-12-31 | (m) | $40.91M | (m) | (m) |
| 2022-09-30 | (m) | $70.53M | (m) | (m) |
| 2022-06-30 | (m) | $30.93M | (m) | (m) |
| 2022-03-31 | (m) | $31.57M | (m) | (m) |
| 2021-12-31 | (m) | $37.41M | (m) | (m) |
| 2021-09-30 | (m) | $15.88M | (m) | (m) |
| 2021-06-30 | (m) | $132.24M | (m) | (m) |
| 2021-03-31 | (m) | $159.56M | (m) | (m) |
| 2020-12-31 | (m) | $171.13M | (m) | (m) |
| 2020-09-30 | (m) | $197.26M | (m) | (m) |
| 2020-06-30 | (m) | $99.86M | (m) | (m) |
| 2020-03-31 | (m) | $117.26M | (m) | (m) |
| 2019-12-31 | (m) | $104.39M | (m) | (m) |
| 2019-09-30 | (m) | $73.72M | (m) | (m) |
| 2019-06-30 | (m) | $55.39M | (m) | (m) |
| 2019-03-31 | (m) | $11.87M | (m) | (m) |
| 2018-12-31 | (m) | $7.62M | (m) | (m) |
| 2018-09-30 | (m) | $11.96M | (m) | (m) |
| 2018-06-30 | (m) | $11.01M | (m) | (m) |
| 2018-03-31 | (m) | $9.61M | (m) | (m) |
| 2017-12-31 | (m) | $10.13M | (m) | (m) |
| 2017-09-30 | (m) | $6.15M | (m) | (m) |
| 2017-06-30 | (m) | $8.31M | (m) | (m) |
| 2017-03-31 | (m) | $10.85M | (m) | (m) |
| 2016-12-31 | (m) | $14.22M | (m) | (m) |
| 2016-09-30 | (m) | $16.80M | (m) | (m) |
| 2016-06-30 | (m) | $18.42M | (m) | (m) |
| 2016-03-31 | (m) | $19.59M | (m) | (m) |
| 2015-12-31 | (m) | $17.33M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |